HDAC9 and gout: Although there are currently no clinical trials of epigenetic drugs specifically targeting gout, trials of HDAC inhibitors have been conducted in rheumatoid arthritis, showing safety, tolerability, and some anti-inflammatory effects (He et al., 2025).